At the recent BioPartner Forum it was stated the internal market is insufficient for a UK Life Science company to develop a technology, product or service at a rate that will return investor value. Do you
According to the BBC (http://news.bbc.co.uk/1/hi/health/10285950.stm), the British Medical Association is questioning the effectiveness of NHS Direct, claiming it delayed patients getting healthcare. Is this where cuts could be made?
